PLAY PODCASTS
Wellness Unmasked Weekly Rundown: FDA Cracks Down on Kratom Derivatives + Controversy Over AI in Healthcare

Wellness Unmasked Weekly Rundown: FDA Cracks Down on Kratom Derivatives + Controversy Over AI in Healthcare

The Clay Travis and Buck Sexton Show

August 1, 20254m 23s

Audio is streamed directly from the publisher (podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.

Show Notes

In this Wellness Unmasked Weekly Rundown, Dr. Nicole Saphier breaks down two urgent developments in the world of health and wellness. First, she unpacks the FDA's move to schedule 7-hydroxymitragynine (7-OH)—a synthetic Kratom derivative up to 13 times stronger than morphine—as a Schedule I controlled substance. What does this mean for wellness supplements, and how did these potent, unregulated substances make it to market in the first place?

Then, Dr. Saphier dives into the White House’s new AI-driven healthcare initiative. While tech giants like Amazon, Google, and Apple promise to revolutionize healthcare with data transparency and streamlined systems, concerns mount over data privacy, conflicts of interest, and regulatory oversight. Are Silicon Valley insiders set to profit from policies they help shape? Wellness Unmasked is part of the Clay Travis & Buck Sexton Podcast Network - new episodes debut every Tuesday & Friday.

Follow Clay & Buck on YouTube: https://www.youtube.com/c/clayandbuck

See omnystudio.com/listener for privacy information.

Topics

FDA 7-hydroxymitragynineKratom ban 2025synthetic opioidsAI in healthcarehealthcare data privacyRFK Jr health policyCallie Means Casey MeansSilicon Valley health startupsCMS data oversighthealth tech corruption.